tetano
Editor, Senior Moderator
J Pediatric Infect Dis Soc. 2013 Dec;2(4):368-78. doi: 10.1093/jpids/pit053. Epub 2013 Sep 24.
[h=1]Overview of Influenza Vaccines in Children.[/h] Lafond KE[SUP]1[/SUP], Englund JA[SUP]2[/SUP], Tam JS[SUP]3[/SUP], Bresee JS[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Prevention of influenza infection through vaccination is the best strategy to reduce its disease burden; however, annual revaccination is required to provide protection from circulating virus strains. Currently available influenza vaccines are trivalent inactivated influenza vaccines (IIV) or live-attenuated influenza vaccines (LAIV); however, quadrivalent formulations of IIV and LAIV are expected to be available for the 2013-2014 influenza season. Among children 6 months through 8 years of age receiving their first influenza vaccination, 2 doses of vaccines are required to provide adequate protection. Because of the wide range of circulating influenza viruses and host immune responses, estimates of vaccine effectiveness vary widely by year, age group, and vaccine studied. We summarize the evidence base for pediatric influenza vaccination, and we describe the challenges and limitations of protecting this population with currently available vaccines.
Published by Oxford University Press on behalf of the Pediatric Infectious Diseases Society 2013. This work is written by US Government employees and is in the public domain in the US.
[h=4]KEYWORDS:[/h] Inactivated Influenza Vaccines; Influenza Vaccines; LAIV; Quadrivalent Vaccines
PMID: 26619499 [PubMed - in process] Free full text
[h=1]Overview of Influenza Vaccines in Children.[/h] Lafond KE[SUP]1[/SUP], Englund JA[SUP]2[/SUP], Tam JS[SUP]3[/SUP], Bresee JS[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Prevention of influenza infection through vaccination is the best strategy to reduce its disease burden; however, annual revaccination is required to provide protection from circulating virus strains. Currently available influenza vaccines are trivalent inactivated influenza vaccines (IIV) or live-attenuated influenza vaccines (LAIV); however, quadrivalent formulations of IIV and LAIV are expected to be available for the 2013-2014 influenza season. Among children 6 months through 8 years of age receiving their first influenza vaccination, 2 doses of vaccines are required to provide adequate protection. Because of the wide range of circulating influenza viruses and host immune responses, estimates of vaccine effectiveness vary widely by year, age group, and vaccine studied. We summarize the evidence base for pediatric influenza vaccination, and we describe the challenges and limitations of protecting this population with currently available vaccines.
Published by Oxford University Press on behalf of the Pediatric Infectious Diseases Society 2013. This work is written by US Government employees and is in the public domain in the US.
[h=4]KEYWORDS:[/h] Inactivated Influenza Vaccines; Influenza Vaccines; LAIV; Quadrivalent Vaccines
PMID: 26619499 [PubMed - in process] Free full text